You are here:

dolutegravir (Tivicay)

Advice

following an abbreviated submission:

dolutegravir (Tivicay®) is accepted for use within NHS Scotland.

Indication under review: in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age.

SMC has previously accepted dolutegravir 50mg film-coated tablets for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

This SMC advice takes account of the benefits of a patient access scheme (PAS) that improves the cost-effectiveness of dolutegravir.  This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: dolutegravir (Tivicay)
SMC Drug ID: 1253/17
Manufacturer: ViiV Healthcare/GSK
Indication: In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age.
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 July 2017

Back